Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.
about
Research resource: Haploinsufficiency of receptor activity-modifying protein-2 (RAMP2) causes reduced fertility, hyperprolactinemia, skeletal abnormalities, and endocrine dysfunction in miceCalcitonin gene-related peptide: physiology and pathophysiologyEpicardial-derived adrenomedullin drives cardiac hyperplasia during embryogenesis.Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis.Possible site of action of CGRP antagonists in migraine.Characteristics of multi-organ lymphangiectasia resulting from temporal deletion of calcitonin receptor-like receptor in adult mice.Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.CGRP receptor antagonists: an expanding drug class for acute migraine?Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex.Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?Calcitonin gene-related peptide receptor antagonists for migraine.Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine.The pathophysiological and pharmacological basis of current drug treatment of migraine headache.Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide ReceptorThe calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion.Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine.BMS-927711 for the acute treatment of migraine.Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program.Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography.CGRP and its receptors.
P2860
Q24603724-DDA8D407-1618-4C38-9D95-5F6475D26BA1Q28249298-35A51943-4511-4E7B-85EC-619726D62EDCQ33564987-E07512CF-CDAC-45E6-B276-C9241FAB0BF3Q34094599-A739D08F-97E0-4DF4-BBB4-2B1BAFB892E1Q34169056-33649DF1-DF1C-4B61-8E56-84445D2A3DD2Q34428530-1A4D4410-3FF5-48CE-B4E1-910B35458FD9Q34446715-873AA8DA-58F7-423D-B6DA-94D77BA838DEQ34637610-90514CAA-1E5D-43C5-BB24-1559F6CE4219Q34897152-18E5B17B-C0AA-4EF4-BFD9-3E1D150A39B4Q35675308-0F116480-A932-4BE0-8C85-32A6979407ACQ37337815-F0282580-064B-488A-A55B-56EB677A12C2Q37756158-42FCE122-1FD0-41F2-9898-135CD5625D27Q37922799-AFC36A09-5080-4B18-967F-E7857A9372F1Q38105147-9145F611-BCA8-4183-9C1D-097BACDB06A9Q38130336-A541ED15-1672-4202-AD04-546F50BCDA7AQ38196732-35464064-8DB0-4DCA-9C92-F2D624561BC0Q39769257-D05D8C23-DF44-4B32-8F88-FD8B2FDCFE5EQ41829270-7CCECDF3-5BF1-444F-A161-2209CF52EA36Q45018129-03DCD5F8-EDDF-4121-A0DD-BF2B90F51A9EQ45137898-7590446C-EE13-4F80-A1B6-95BDA1F56748Q46698001-2C621188-980B-4986-A104-E438AA0663E5Q48113165-40316533-6641-4CC7-BB19-6630A0ADF01CQ48198655-EC74C556-24B7-42CC-90F5-A9E670A489F8
P2860
Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacological properties of ...... d peptide receptor antagonist.
@ast
Pharmacological properties of ...... d peptide receptor antagonist.
@en
Pharmacological properties of ...... d peptide receptor antagonist.
@nl
type
label
Pharmacological properties of ...... d peptide receptor antagonist.
@ast
Pharmacological properties of ...... d peptide receptor antagonist.
@en
Pharmacological properties of ...... d peptide receptor antagonist.
@nl
prefLabel
Pharmacological properties of ...... d peptide receptor antagonist.
@ast
Pharmacological properties of ...... d peptide receptor antagonist.
@en
Pharmacological properties of ...... d peptide receptor antagonist.
@nl
P2093
P356
P1476
Pharmacological properties of ...... d peptide receptor antagonist.
@en
P2093
Amy Calamari
Andrew Danziger
Christopher A Salvatore
Cyrille Sur
David L Williams
Eric L Moore
Harold G Selnick
Ian M Bell
Jacquelynn J Cook
John F Fay
P304
P356
10.1124/JPET.109.163816
P407
P577
2010-01-11T00:00:00Z